TScan Therapeutics (TCRX) news
Recent news
Tscan Therapeutics, Inc.: H.C. Wainwright cuts to neutral from buy
H.C. Wainwright & Co. has revised its rating for Tscan Therapeutics, Inc. (NASDAQ: TSCR) from "Buy" to "Neutral," reflecting a reassessment of the company's near-term prospects and market dynamics. The downgrade comes amid ongoing clinical development for Tscan's pipeline, which includes TTI-100, a…
AInvest Wire · Sep 8, 2026Tscan Therapeutics Inc: Wedbush cuts to neutral from outperform; cuts target price to $1 from $5
TScan Therapeutics Inc. (TCRX) has seen recent shifts in analyst sentiment, with Wedbush downgrading its recommendation to "neutral" from "outperform" and reducing its price target to $1 from $5. This adjustment reflects a reassessment of the company's near-term prospects amid ongoing financial…
AInvest Wire · Sep 2, 2026Tscan pauses phase 3 alloha-2 trial
AInvest Wire · Sep 2, 2026Tscan Therapeutics announces strategic reorganization
AInvest Wire · Sep 2, 2026Tscan Therapeutics - Pauses enrollment in phase 3 alloha-2 study of TSC-101 due to insufficient capital
TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced the temporary pause of enrollment in its Phase 3 ALLOHA-2™ trial of TSC-101, a T cell receptor (TCR)-engineered T cell therapy candidate for the treatment of residual disease following allogeneic hematopoietic cell transplantation (allo-HCT) in…
AInvest Wire · Sep 2, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.